PMID: 9549662Apr 29, 1998Paper

Pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease

Journal of Clinical Pharmacology
L C PettigrewB Gulanski

Abstract

Metrifonate is converted nonenzymatically to 2.2, dimethyl dichlorovinyl phosphate (DDVP), an inhibitor of acetylcholinesterase (AChE). This 21-day, randomized, double-blind, placebo-controlled trial of metrifonate in patients with Alzheimer's disease (n = 27) evaluated four doses, each administered orally once daily. All patients received a loading dose (LD) for 6 days followed by a maintenance dose (MD) for 15 days. The treatment groups were: panel 1, LD = 1.5 mg/kg (75-135 mg), MD = 0.25 mg/kg (12.5-25 mg); panel 2, LD = 2.5 mg/kg (125-225 mg), MD = 0.40 mg/kg (20-35 mg); panel 3, LD = 4.0 mg/kg (200-335 mg), MD = 0.65 mg/kg (30-60 mg); and panel 4, LD = 4.0 mg/kg (200-335 mg), MD = 1.0 mg/kg (50-90 mg). All metrifonate doses were well tolerated. Most adverse events were mild to moderate in intensity, gastrointestinal in nature, and transient. Mean area under the concentration-time curve (AUC) and maximum concentration (Cmax) for both metrifonate and DDVP increased in relation to dose. Metrifonate and DDVP had similar, largely dose-independent mean values for time to Cmax (tmax) and half-life (t1/2). There was little or no accumulation of either metrifonate or DDVP with long-term administration. After 21 days of treatment, m...Continue Reading

References

Mar 26, 1977·Lancet·P WhiteD M Bowen
Oct 13, 1978·Archives of Toxicology·B HolmstedtA Sundwall
Oct 13, 1978·Archives of Toxicology·I NordgrenM Sandoz
Sep 1, 1975·Archives of Neurology·V C HachinskiL Symon
Nov 1, 1975·Journal of Psychiatric Research·M F FolsteinP R McHugh
Nov 11, 1992·JAMA : the Journal of the American Medical Association·M FarlowJ Dolan-Ureno
Nov 13, 1986·The New England Journal of Medicine·W K SummersA Kling
Jun 1, 1987·Neuropharmacology·M Hallak, E Giacobini
Jul 1, 1968·The British Journal of Psychiatry : the Journal of Mental Science·G BlessedM Roth
Nov 1, 1984·The American Journal of Psychiatry·W G RosenK L Davis
Feb 1, 1983·Journal of Neurochemistry·N R SimsA N Davison
Sep 17, 1994·Lancet·P Jenner
Jan 1, 1994·Neurobiology of Aging·J W PettegrewL R Muenz
Jun 1, 1994·Neurology·W D ParkerB K Kleinschmidt-DeMasters
Jul 1, 1961·Biochemical Pharmacology·G L ELLMANR M FEATHER-STONE
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON

❮ Previous
Next ❯

Citations

Jun 29, 2000·Journal of Chromatography. B, Biomedical Sciences and Applications·R HeinigG J Krol
Jun 11, 2004·Clinical Neuropharmacology·Roger M LaneNigel H Greig
May 28, 2009·Learning & Memory·Catherine C Kaczorowski, John F Disterhoft
May 20, 1999·The Annals of Pharmacotherapy·W J KrallN R Cutler
Oct 31, 2002·Human Psychopharmacology·Alain Patat
Jun 23, 2001·Journal of Geriatric Psychiatry and Neurology·J L CummingsP A Cyrus
Apr 21, 2006·The Cochrane Database of Systematic Reviews·J M López-Arrieta, L Schneider
Oct 1, 2008·Journal of Enzyme Inhibition and Medicinal Chemistry·Miroslav PohankaKamil Kuca
Jan 12, 2001·Journal of Neurophysiology·J M PowerJ F Disterhoft
Nov 30, 2000·Current Treatment Options in Neurology·A S Schachter, K L Davis
Oct 17, 2007·Environmental Science & Technology·Qingzhu ZhangWenxing Wang

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.